Halozyme Therapeutics HALO Deferred Taxes
Deferred Taxes at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredIncomeTaxes.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's deferred taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's deferred taxes?
- Halozyme Therapeutics (HALO) reported deferred taxes of -$3.43M in Q1 2026.
- How has Halozyme Therapeutics's deferred taxes changed year-over-year?
- Halozyme Therapeutics's deferred taxes decreased by 219.9% year-over-year, from $2.86M to -$3.43M.
- What is the long-term trend for Halozyme Therapeutics's deferred taxes?
- Over 2 years (2021 to 2023), Halozyme Therapeutics's deferred taxes has grown at a -52.9% compound annual growth rate (CAGR), from $155.43M to -$34.51M.
- What does deferred taxes mean?
- The non-cash accounting adjustment for future tax obligations or benefits.
- How do you interpret deferred taxes?
- A significant change indicates a shift in the timing of tax recognition versus actual cash tax payments.
- How does deferred taxes compare across companies?
- Standard line item across all industries; varies based on depreciation methods and tax jurisdiction rules.